1Tumer HE, Nagy Z, Esiri MM, et al. Role of matrix metalloproteinase 9 in pituitary tumor behavior[J].J Clin Endocrinol Metab, 2000,85(8) : 2931 -2935.
2Li C, Guo B, Bemabeu C, et al. Angiogenesis in breast cancer: the transforming growth factor beta and CD105[J]. Microsc Res Tech, 2001,52(4) :437 -449.
3Farias E, Ranuncolo S, Creta C, et al. Plasua metaUproteinase activity is enhanced in theeuglobulin fraction of breast and lung cancer patients[J]. Int J Cancer, 2000,89:389 -394.
4Visse R,Nagase H. Matrix metaUoproteinases and tissue inhibitors of metalloproteinases : structure, function, and biochemistry [ J ]. Circ Res ,2003,92:827 - 839.
5Nielsen BS. Expression of matrix metalloproteinase - 9 in vascular pericytes in human breast cancer[ J ]. Lab Invest, 1997,77:345 - 355.
7Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy [J]. J Natl Cancer Inst,2001,93(3) : 178 - 193.
8Lioffa. Isolation of a protein that stimulates blood vessel growth[J].Nature,1985,318 (6041): 14.
9Powell WC, Knox JD, Navre M, et al. Expression of the metalloproteinases matrilysis in Dn - 145 cells increases their invasive potential in severe combined immunodeficient mice [ J ]. Cancer Res,1993, 53:417 -422.
10Nuttall RK, Penning, ton CJ, Taplin J, et al. Elevated membrane type metrix metal - loproteinases in gliomas revealed by profiling proteasea and inhibitor in human cancer cell[J].Mol Cancer Res, 2003,1(5): 333-345.
二级参考文献40
1刘彤华 李维华.诊断病理学[M].北京:人民卫生出版社,1995.935.
2Turner HE,Nagy Z,Esiri MM, et al. Role of matrix metalloproteinase 9 in pituitary tumor behavior[J]. J Clin Endocrinol Metab, 2000,85 ( 8 ) : 2931-2935.
3Sato F, Shimada Y, Watanabe G, et al. expression of vascular endothelial growth factor, matrix metalloproteinase-9 and Ecadherin in the process of lymph node metastasis in oesophageal cancer[J]. Br J Cancer, 1999, 80(9):1366-1372.
4Hedinger C,Williams ED,Sobin LH,et al. The WHO histological classification of thyroid tumors:a commentary on the second edition[J]. Cancer, 1989,63:908-911.
5Weidner N, Semple JP, Welliam WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma[J]. N Engl J Med,1991,324:1-8.
6Kossakowska AE,Huchcroft SA,Urbanski SJ,et d. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia,sporadic colorectal neopalsia,pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans[J]. Br J Cancer, 1996,73:1401-1408.
7Wong NA, Willott J, Kendall M J, et al.measurement of vascularity as a diagnostic and prognostic tool for well differentiated thyroid turnouts:comparison of different methods of assessing vascular[J]. J Clin Pathol, 1999,52:593-597.
3Pieras E. Management and prognosis of urothelial carcinoma superficial recurrence in muscle--invasive bladder cancer after bladder preservation[J]. Eur Urol, 2003,44 (2) : 222 -225.
4EbleJ N, Sauter G, Epstein JI, et al. World Health Organization Classification of tuors of the urinary system and male genital organs[M]. IARC, 2004,32(5) : 90-123.
5Kurt JS,Arieh AK,Bruce H,et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: Autocrine/paracrine regulation of cyclooxygenase-2, prostagland in E receptors and angiogenic factors by cyclooxygenasel[J]. Cancer Res,2002,15(62) : 424-432.
